Introduction to Molecular Adsorbent Recirculating System Albumin Dialysis
This podcast will describe the principle of albumin dialysis of the molecular adsorbent recirculating system (MARS). Host Pamela M. Peeke, MD, MPH, FACP, FACSM, is joined by Ram M. Subramanian, MD, MBA, FCCM, to discuss the logistics of starting a MARS program to outline indications for MARS. Dr. Subramanian is a hepatologist at Emory University in Atlanta, Georgia. This podcast is sponsored by Baxter.
Extracorporeal Blood Purification
Host Pamela Peeke is joined by Dr. Neyra to discuss clinical cases and the use of extracorporeal blood purification in COVID-19 patients. Dr. Neyra is an Acute Care Nephrology and CRRT Program and Assistant Professor at the University of Kentucky Medical Center in Lexington, Kentucky.View resource
HF20 Filter Set for CRRT in Low Weight Patients
This podcast discusses patients who develop acute kidney injury (AKI) and how AKI is independently associated with mortality in critically ill infants, neonates, and larger children. Host Pamela M. Peeke, MD, MPH, FACP, FACSM, is joined by Stuart Goldstein, MD, to discuss the HF20 study, including its end points and the clinical gaps the study addresses.View resource
Citrate and Continuous Renal Replacement Therapy
With widespread utilization of continuous renal replacement therapy, it's critical to know about how citrate may have a role. Host Pamela M. Peeke, MD, MPH, FACP, FACSM, is joined by Ashita Tolwani, MD, to review citrate and its role in the anticoagulation process and how it can decrease the likelihood of adverse events and ease clinician workload. Dr. Tolwani is a nephrologist at the University of Alabama in Tuscaloosa, Alabama, USA.View resource
The PRISMAFLEX HF20 Set has been authorized by the FDA under an Emergency Use Authorization to provide continuous renal replacement therapy (CRRT) to treat low weight (8-20 kg) and low blood volume patients or patients who have acute renal failure, fluid overload, or both, and who cannot tolerate a larger extracorporeal circuit volume in an acute care environment during the Coronavirus Disease 2019 (COVID-19) pandemic. The PRISMAFLEX HF20 Set has neither been cleared or approved to provide CRRT in an acute care environment. The PRISMAFLEX HF20 Set is authorized for use for no longer than the duration of the COVID-19 public health emergency, as deemed by the Secretary of the Department of Health and Human Services (HHS).
The OXIRIS Set device is authorized under EUA200164 (Emergency Use Authorization) to treat patients 18 years of age or older with confirmed Coronavirus Disease 2019 (COVID-19) infection admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure in need of blood purification, including use in continuous renal replacement therapy. This device has neither been cleared or approved for the indication to treat patients with COVID-19 infection. The device is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the OXIRIS Set under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
REGIOCIT has been authorized by FDA for emergency use. REGIOCIT is not FDA-approved. REGIOCIT is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of REGIOCIT under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, REGIOCIT: a replacement solution that contains citrate for Regional Citrate Anticoagulation (RCA) of the extracorporeal circuit. REGIOCIT has been authorized for emergency use as a replacement solution in adult patients treated with Continuous Renal Replacement Therapy (CRRT), and for whom RCA is appropriate, during the COVID-19 pandemic. REGIOCIT is intended for use in a critical care setting. REGIOCIT is intended to be used in continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodiafiltration (CVVHDF) modalities. Use of REGIOCIT is limited to healthcare providers and/or institutions that Baxter has qualified to administer REGIOCIT for these emergency uses.